Patients with newly diagnosed Rheumatoid Arthritis are at increased risk of Diabetes Mellitus:An Observational Cohort study by Emamifar, Amir et al.
Syddansk Universitet
Patients with newly diagnosed Rheumatoid Arthritis are at increased risk of Diabetes
Mellitus
An Observational Cohort study
Emamifar, Amir; Levin, Klaus; Jensen Hansen, Inger Marie
Published in:
Acta Reumatologica Portuguesa
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Citation for pulished version (APA):
Emamifar, A., Levin, K., & Jensen Hansen, I. M. (2017). Patients with newly diagnosed Rheumatoid Arthritis are
at increased risk of Diabetes Mellitus: An Observational Cohort study. Acta Reumatologica Portuguesa, 42, 310-
317.
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 08. Jan. 2018
ÓRGÃO OfICIAL dA SOCIEdAdE PORTUGUESA dE REUMATOLOGIA
310
ARTIGO ORIGINAL
1. Rheumatology, Odense University Hospital, Svendborg Hospital 
2. Endocrinology, Odense University Hospital, Svendborg Hospital
(P <0.001) and RA disease duration ≥4 years (P =0.05).
We did not find any significant associations between
presence of DM and gender, RF, anti-CCP, as well as,
ANA. Additionally, presence of DM in the RA patients
was not a negative predictor of treatment response mea-
sured by the European League Against Rheumatism
(EULAR) response criteria and DDAS28-CRP.
Conclusion: Newly diagnosed RA patients are at 
hi gher risk of DM (13% versus 5.7% in Denmark), and
a high index of suspicion must be kept.
Keywords:  Rheumatoid arthritis; Diabetes mellitus;
DAS28; RF; Anti-CCP
IntroductIon
Rheumatoid arthritis (RA) is a systemic, autoimmune
disease, characterized by articular and, in some cases,
extra-articular manifestation, with a prevalence of 0.5-
-1% in the general population. It has been generally
accep ted that RA should be diagnosed and managed
promptly. The ultimate goal of treatment is to prevent
or control joint destruction and subsequent functio nal
loss1. There has been a major improvement in the long
term prognosis of RA, since the introduction of highly
effective disease modifying anti-rheumatic drugs
(DMARDs) and by improved management strategies
such as tight control and treat-to-target2,3. However
long-term prognosis can be affected by different co-
morbidities, leading to increased rate of mortality in
comparison with the general population. Cardiovascu-
lar disease, infections and certain kinds of malignan-
cies, are the main causes of excess mortality rate in RA
patients4-6. Comorbidities may be related to the disease
characteristic itself or occur as a results of treatment.   
Diabetes mellitus (DM) is a metabolic disease caused
by deficiencies in insulin secretion, action or both, re-
Patients with newly diagnosed rheumatoid arthritis 
are at increased risk of diabetes mellitus: 
an observational cohort study
Emamifar A1, Levin K2, Jensen Hansen IM1
ACTA REUMATOL PORT. 2017;42:310-317
AbstrAct
Aims: To reveal the prevalence of diabetes mellitus (DM)
in patients with newly diagnosed rheumatoid arthritis
(RA) and evaluate the association between cli nical cha -
racteristics of RA and DM, as well as, treatment response
in newly diagnosed RA patients with DM.
Methods: Newly diagnosed, adult, RA patients, who
were registered in Danish Danbio since 1st January 2010,
were included. Patients’ demographics, serology results
including rheumatoid factor (RF), anti-cyclic citrullina -
ted peptide antibody (anti-CCP) and antinuclear antibo -
dy (ANA), as well as, disease activity score in 28 joints-
-C-reactive protein (DAS28-CRP), at the time of
diagnosis and after 4 months (±1-2 months) of treatment
initiation, were extracted from Danbio Regis try. To re-
veal the presence of DM, patients’ electronic medi cal
records were reviewed. The prevalence of DM in our pa-
tients was compared (using an age- and gender-matched
analysis) with that expected from Danish popu lation.
Results: of 439 included patients, 60.1% were female,
mean of age 64.6±15.0 years and RA disease duration
2.6±1.7 years. Prevalence of DM was 57/439 (12.9%),
herein type II DM 52 (91.2%) and type I DM 5 (8.8%).
Except for two patients, diagnosis of DM was esta -
blished prior to the diagnosis of RA. The prevalence of
DM in newly diagnosed RA patients of all ages was
signi ficantly increased versus that expected from Da -
nish population (RR=2.21, CI=1.40-3.42, P <0.001).
In addition, prevalence of DM was significantly increa -
sed with more than twice of the expected for RA pa-
tients aged 65-84. Both genders showed increased risk
of DM after subgroup analysis. The presence of DM in
RA patients was significantly associated with age 
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sulting in disturbances of carbohydrate, fat, and pro-
tein metabolism. The vast majority of DM cases con-
sist of type I, characterized by absolute insulin defi-
ciency, and type II, characterized by insulin resistance
and relative insulin deficiency7. There is no consensus
regarding the prevalence of DM in RA, how -ever most
of the previous studies support the increased preva-
lence of DM or insulin resistance in RA, caused by im-
mune system activation and/or RA treatment8,9. Tumor
necrosis factor alpha (TNF) is a mediator of insulin re-
sistance and play a significant role in the pathogenesis
of RA10,11. On the other hand, TNF inhibitors reduce
the risk of developing DM in RA patients, which sug-
gests a role for TNF in the pathogenesis of RA and
DM12. Co-occurrence of DM among RA patients is as-
sociated with increased risk of cardiovascular disease13.
Considering the possible relationship between RA
and DM, an early diagnosis of DM can substantially
improve long-term prognosis, and moreover reduce
the economic burden and mortality rate of RA patients.
The primary objective of this study was to investigate
the prevalence of DM in newly diagnosed RA patients.
The secondary objectives of this study were to evalua -
te the association between clinical characteristics of RA
and DM, as well as, treatment response in RA patients
with diagnosed DM. 
mAterIAls And methods
dAnbIo
The Danish Danbio registry was established in 2000
and approved by the National Board of Health (file no.
7-201-03-12/1) and Danish Data Protection Agency
(file no. 2007-58-0014 and file no. 2007-58-0006). It
provides national data on the disease course of patients
with inflammatory rheumatic disease including RA,
ankylosing spondylitis and psoriatic arthritis, via per-
sonal identification code. In addition to its value in
routine clinical care, it provides an effective and 
powerful research database at the same time. Data in
Dan bio are categorized to baseline variables (e.g. de-
mographic data, diagnosis, diseases duration) and lon-
gitudinal/follow-up data (e.g. treatment, functio nal sta-
tus and disease activity scores) and collected by onli ne
registration from patients and health personnel at eve -
ry consultation.14 All departments of rheumatology in
Denmark are required to register every newly diagno -
sed RA patient in Danbio, however each department
has only access to its own patients. At our department,
all patients with diagnosis of RA are registered in Dan-
bio, at every consultation. 
study desIgn And settIng 
This is an observational, cohort, single center study.
The whole parts of the study were performed at the
rheumatology outpatient clinic, Svendborg Hospital,
Denmark, in December 2015. Ethical approval was
obtained from Danish Data Protection Agency (file
no.14/50243) and Danish Patient Safety Authority (file
no.3-3013-1542/1/).
PArtIcIPAnts 
The diagnosis of RA was made according to the new
2010 American College of Rheumatology/European
League Against Rheumatism classification criteria for
RA. All our RA patients registered in the Danbio
database were considered to enter into the study15. The
following inclusion criteria were applied: 1) Patients
who were registered at the rheumatology outpatient
clinic and 2) Adult patients who were diagnosed with
RA since 1st January 2010 according to the new crite-
ria. Patients who passed away or were referred to the
other departments were also included in the study. Ex-
clusion criteria were patients who diagnosed with RA
before 1st January 2010 and those with juvenile RA.  
InItIAl rheumAtoId ArthrItIs treAtment
At our rheumatology outpatient clinic, patients with
newly diagnosed RA are treated with methotrexate,
which may be increased to 25 mg per week, depen ding
on disease monitoring using disease activity score in 28
joints-C-reactive protein (DAS28-CRP), as an index of
disease activity. Additionally, hydroxychloroquine, sul-
fasalazine as well as prednisolone (given Intramuscu-
lar, intraarticular or orally) can be added in case of per-
sistent disease activity. The treatment goal is to achieve
remission i.e. DAS28-CRP less than 2.6 (or low di sease
activity i.e. DAS28-CRP≤3.2) as quickly as possible.
dAtA collectIon
For each patient data on demographics (age, sex, year
of RA diagnosis), serology test results including
rheumatoid factor (RF), anti-cyclic citrullinated pepti -
de antibody (anti-CCP) and antinuclear antibody
(ANA) were collected. DAS28-CRP at the time of di-
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standard deviation (±SD), categorical data as frequen-
cies and respective percentages. Student’s t-test was
used to compare the above mentioned variables, be-
tween RA patients with and without DM. When com-
paring two binary variables the Chi-square test was per-
formed.
The expected number of patients with DM for our
cohort was estimated by multiplying the Statens Serum
Institut’s rate of DM for each age group, as well as, 
gender by the number of RA patients within those
subgr oups. Subsequently, relative risk (RR) for each
subgro up was expressed as the ratio of observed to ex-
pected cases. P value was considered as significant if 
P ≤0.05. In case of missing data we used pairwise dele-
tion to keeps as many cases as possible for each analysis. 
results 
Of 974 RA patients registered in the regional part of
Danbio, 439 patients, who were diagnosed according
to the new criteria, met the inclusion criteria and had
none of the exclusion criteria. 535 patients were ex-
cluded from the study since RA diagnosis was esta -
blished before 1st January 2010. Demographics, disea -
se characteristics and response to treatment of included
patients are summarized in Table I. 
The prevalence of DM, in the present cohort study,
was 57/439 (12.9%), of which 52 (91.2%) and 5
(8.8%) patients were diagnosed with type II and type
I respectively. Of 57 patients, 9 patients had HbA1C
≥6.5% without receiving antidiabetic medication and
11 patients were prescribed prednisolone with an ave -
rage of 6.8±2.4mg/day. All 11 patients who received
prednisolone had type II DM. RA patients with type I
(n=5) were all positive for RF.
Using an age- and gender-matched analysis, preva-
lence of DM in our cohort was compared with the
prevalence of DM expected based on available data
from Statens Serum Institut (Table II). For patients of
all ages with newly diagnosed RA, there was a signifi-
cant increase in the prevalence of diabetes, with more
than twice the expected number of patients with DM
(RR=2.21, 95% confidence interval =1.40-3.42, 
P <0.001)). Statistically significant differences were
found in RA patients aged 65-84, irrespective of the
gender.
As expected, RA patients with DM were significant-
ly older than patients with isolated RA. The results of
our study revealed that RA disease duration ≥4 years
agnosis and after 4 months (±1-2 months) of treatment
initiation were also gathered. The actual dosage of pred-
nisolone was obtained, if patients received predni -
solone.    
The electronic medical records of the patients were
reviewed for a positive history of DM as well as pres -
cribed antidiabetic medications and abnormal lab tests
(fasting blood sugar (FBS) and hemoglobin A1C
(HbA1C)) to identify if the patients had been diagnosed
with DM as well. Types of DM and year of DM diagno-
sis were extracted from Fyns Diabetes Database.
Diagno sis of DM was made at the department of endo -
crinology according to international standards7.
To compare the prevalence of DM in the group of pa-
tients with newly diagnosed RA at our outpatient cli nic
with prevalence of DM in Danish population, we cal-
culated expected number of DM for our cohort study
based on available data from Statens Serum Ins titut16. 
VArIAbles
Demographic data were extracted from Danbio. The
results of RF (normal range: <15 IU/mL), anti-CCP
(normal range: <20 EU/mL) and ANA (normal range:
<1/0 IU), were collected and analyzed both quantita-
tive and qualitative (positive/negative). DAS28-CRP
and DDAS28-CRP were also calculated:17
DDAS28-CRP =DAS281-CRP (at the time of diagnosis)
– DAS284-CRP (after 4 months of treatment initiation
±1-2 months). The lower reporting limit of CRP was
considered as <10 mg/L.18
We considered following reference values for FBS
(<126 mg/dl) and HbA1C (<6.5%).  
the euroPeAn leAgue AgAInst 
rheumAtIsm (eulAr) resPonse crIterIA
The EULAR response criteria classify the RA patients as
non-, moderate or good responders dependent on the
change and the level of the disease activity score du ring
the time19. In the present study additionally to
DDAS28-CRP, EULAR response criteria were used to
assess the treatment response in the RA patients.  
stAtIstIcAl AnAlysIs
We used Microsoft Excel 2010 to perform statistical
analysis. Continuous data were presented as mean ±
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tAble I. demogrAPhIc And dIseAse chArActerIstIcs of the Included PAtIents
Number of patients (n) =439
Age (years), Mean ± SD:   64.6±15.0
0-24 n=5 20.6±0.5   
25-34 n=14 29.7±3.2
35-44 n=26 39.3±3.3
45-54 n=58 50.9±2.9 
55-64 n=94 59.4±2.9
64-74 n=121 70.0±2.7 
75-84 n=91 78.9±2.8 
85+   n=30 88.3±2.9  
Gender (%)
Female             264 (60.1%)
RA disease duration (years), Mean ± SD:        2.6±1.7
DAS281-CRP, Mean ± SD:        4.4±1.3
DAS284-CRP, Mean ± SD:        3.0±1.2
DDAS28-CRP, Mean ± SD: 1.4±1.4
IgM RF (%)
Positive 244 (55.6%)
Negative 195 (44.4%)
Anti-CCP (%)
Positive 197 (44.9%)
Negative 241 (54.9%)
No data 1 (0.2%)
ANA (%)
Positive 85 (19.4%)
Negative 327 (74.5%)
No data 27 (6.1%)
a) RA: rheumatoid arthritis b) DMARDs: disease modifying antirheumatic drugs c) DAS281-CRP: disease activity score in 28 
joints-C- reactive protein at the time of diagnosis d) DAS284: disease activity score in 28 joints-C-reactive protein after 4 months of
treatment initiation ±1-2 months e) DDAS28-CRP: DAS281-CRP (at the time of diagnosis) – DAS284-CRP (after 4 months of treatment
initiation ±1-2 months) f) RF: rheumatoid factor g) Anti-CCP: anti-cyclic citrullinated peptide antibody and h) ANA: antinuclear antibody
tAble II. PreVAlence of dIAbetes In PAtIents wIth newly dIAgnosed rheumAtoId ArthrItIs 
comPAred to the PreVAlence of dm exPected from dAnIsh PoPulAtIon 
Observed number Expected number  
of patients with DM of patients with DM Relative Risk 95% CI P value
All patients 57 26 2.21 1.40-3.42 <0.001
Age (y)
45-54 2 2 1.19 0.15-6.86 1.00
55-64 9 5 1.80 0.63-5.17 0.26
65-74 22 9 2.35 1.17-5.09 0.01
75-84 19 8 2.39 1.10-5.15 0.02
85+ 5 2 2.75 0.52-11.89 0.22
Gender
Male 28 13 2.62 1.15-4.02 0.01
Female 29 13 2.63 1.19-4.19 0.01
DM: Diabetes mellitus, CI: Confidence Interval
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patients of all ages, after age- and gender-matched ana -
lysis, 3) both genders showed a higher risk of DM com-
pared to the expected from Danish population, 4) el-
der RA patients with disease duration ≥4 years were at
increased risk of DM compared to younger patients
with disease duration <4 years and 5) Presence of DM
in the RA patients was not associated with worse ini-
tial treatment response measured by the EULAR res -
ponse criteria and DDAS28-CRP compared to the pa-
tients with isolated RA.
The overall prevalence of DM among RA patients
was estimated to be about 13% in this study; howe ver,
with respect to the prevalence of DM in RA patients
there were still controversies in the previous studies.
Han et al, in a cross sectional study of 28,208 RA pa-
tients compared with controls matched 4:1 for age, sex,
geographic region, and length of time in plan found a
significantly increased prevalence of DM in RA patients
(10.4% versus 7.6%, P value: 0.01)9. A recent meta-
-analysis  by Jiang P et al, including 11 case control and
8 cohort studies, revealed the increased risk of DM
(both type I and II) in RA. The pooled risk estimate of
case-control and cohort studies demonstrated a statis-
tically significant higher prevalence of DM among RA
individuals (Odds ratio=1.40, 95% Confidence inter-
val: 1.34-1.47 and Risk ratio =1.43, 95% confidence in-
was significantly associated with higher prevalence of
DM, since patients who were diagnosed before 2012
had higher prevalence of DM in comparison with pa-
tients who were diagnosed within 2012 and later. There
were no statistically significant associations between
presence of DM and gender, RF, anti-CCP, ANA,
DDAS28-CRP as well as EULAR response to treatment
(Table III). 
In two RA patients with DM, diagnosis of RA was
made prior to the diagnosis of DM, in which one of
them was prescribed prednisolone 10 mg/day. In rest
of the patients, diagnosis of DM was established before
patients were diagnosed with RA (to the extent that
data were available) (Figure 1).
dIscussIon And conclusIon
This is the first cohort study, evaluating the association
between clinical characteristic of RA and DM as well as
treatment response in newly diagnosed RA patients
with DM.  The main results of this study can be sum-
marized as follows: 1) considering the prevalence of
DM in Danish population (5.7%), DM was more preva-
lent among RA patients (12.9%), 2) there was an in-
creased prevalence of diabetes in newly diagnosed RA
tAble III. AssocIAtIon of dIAbetes mellItus wIth gender, dIseAse durAtIon, rf, AntI-ccP, AnA,
DdAs28-crP And eulAr resPonse crIterIA In rheumAtoId ArthrItIs PAtIents In eAch grouP 
N=439 With diabetes: n=57 Without diabetes: n=382 P value
Age, Mean±SD 72.2±9.0 63.5±15.4 <0.001
Gender (%)
Female 29 (50.9%) 235 (61.5%) 0.50
Disease duration 0.05
≥4 years (%) 27 (47.4%) 130 (34.0%)
<4 years (%) 30 (52.6%) 252 (66.0%)
RF positive (%) 33 (57.9%) 211 (55.2%) 0.84
Anti-CCP positive (%) 25 (43.9%) 172 (45.0%) 0.91
ANA positive (%) 10 (17.5%) 75 (19.6%) 0.75
DAS281-CRP, Mean±SD 4.6±1.4 4.3±1.2 0.17
DAS284-CRP, Mean±SD 3.1±1.2 3.0±1.1 0.43
DDAS28-CRP, Mean±SD 1.5±1.5 1.4±1.4 0.64
Eular response criteria 0.84
Good response 19 (33.3%) 121 (31.7%)
No response  14 (24.6%) 88 (23.0%)
a) RF: rheumatoid factor b) Anti-CCP: anti-cyclic citrullinated peptide antibody c) ANA: antinuclear antibody d) DDAS28-CRP:  
DAS281-CRP (at the time of diagnosis) – DAS284-CRP (after 4 months of treatment initiation ±1-2 months) e) DMARDs: Disease 
Modifying Antirheumatic Drugs f) Eular: European League Against Rheumatism and g) SD: Standard Deviation
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terval: 1.38-1.47 respectively)8. On the contrary,
Solomon et al in a prospective longitudinal cohort
study did not find any significant difference in the
prevalence of DM among women with RA (n=287) and
without RA (n=87,019) participating in the nurses’
health study (4.8% versus 4.4%)20. These controver-
sies might be due to diversity of study populations
mainly ethnicity or other factors related to disease
characte ristic e.g. disease duration.
There was a significant association between age and
presence of DM in RA patients. This finding is consis-
tent with the fact that prevalence of DM increases with
age21. Aging has been reported as to be associated with
deterioration in glucose tolerance22,23. Based on our re-
sults older RA patients, who tended to have longer di -
sease duration were more likely to have diabetes. These
results were in line with a cohort study by Ranganath
VK et al examined 1548 RA subjects with varying disea -
se duration for 33 comorbidities including diabetes. In
Ranganath VK’s study, the prevalence of diabetes was
reported as 9.3%. They also found that aging was signi -
ficantly associated with longer disease duration and
greater number of comorbidities (P value ≤0.001)24.
Diagnosis of RA at initial presentation and starting
treatment at earlier stage is extremely important to pre-
vent further joint destruction. The first few months of
treatment initiation has significant impact on the long
term prognosis25. Previous studies demonstrated that
patients with lower disease activity achieved in the 6
months of treatment initiation had better long term
fIgure 1. Rheumatoid arthritis (RA) and Diabetes (DM) years of diagno sis for each individual RA patient with DM (to the extent
that data were available). As shown, in two patients diagnosis of RA was made prior to the diagnosis of DM (green squares)
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outcome and a clinical remission within 3 to 6 months
of treatment initiation, halts the progression of joint
damage26,27. The authors implemented the concept of
DDAS28-CRP, representing treatment outcome after 4
months, on the importance of the first few months 
after treatment initiation. In this study, however, we did
not find any association between presence of DM and
DAS28-CRP at time of diagnosis or after 4 months 
(±1-2 months) of treatment initiation and subsequently,
DDAS28-CRP had no significant difference between RA
patients with and without diabetes. Besides, assessment
of treatment outcome according to the EULAR response
criteria was also in favor of that presence of DM in this
RA population was not a negative predictor of treat-
ment response.
The exact pathophysiology of DM among RA patient
is not clearly understood, however the role of immune
system activation and proinflammatory mediators (e.g.
TNF, interleukin 1 and Interleukin 6) are well docu-
mented in RA.28 In obese patients, excess lipid accu-
mulation may cause low grade inflammatory process,
resulting in increased production of inflammatory cy-
tokines e.g. TNF and interleukin 6, which can lead to
insulin resistance, impaired glucose tolerance as well as
diabetes. Additionally, liver immune cells produce
proinflammatory cytokines in response to inflamma-
tory mediators secreted by adipose tissue. Certain num-
ber of these proinflammatory cytokines play key roles
in the pathogenesis of RA29. In this study, we included
only newly diagnosed RA patients based on 2010 clas-
sification criteria. However, further research, with in-
clusion of all RA patients regardless of which classifi-
cation criteria is used, should be performed to elucidate
the link between RA and DM considering the other risk
factors such as body mass index or other features of
metabolic syndrome.         
Steroids are commonly used in the treatment of pa-
tients with RA. Though steroids conventionally cause
increase in plasma glucose, the anti-inflammatory effect
of steroids may theoretically increase the secretion of
insulin pancreatic cell and improve peripheral insulin
sensitivity30. Toms TE et al on a cross sectional study of
398 RA patients did not find any association between
long-term steroid exposure and higher prevalence of
the metabolic syndrome, however Dessein PH et al
demonstrated that high oral prednisolone (cumulative
dose 4.8 g (range 2.0-8.5)) and high doses of pulsed
glucocorticoids is related to decreased insulin sensiti -
vity in RA patients.31,32 Based on our results the authors
cannot assuredly rule out the role of steroid treatment
in the development of DM, but in almost all patients,
DM was diagnosed before starting steroids.  Short term
use of steroids in early RA patients allows better disease
activity control without significant increase in the risk
of DM development, which may be explained by an
improvement in insulin resistance as suggested by
Svenson KL et al33.
Both RA and DM are risk factors for cardiovascular
disease34. Considering the higher prevalence of DM
among RA patients found in this study, the authors pro-
pose routine screening for DM i.e. either measurement
of HbA1C or FBS at diagnosis and with yearly interval
thereafter in all RA patients.          
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